The need for axillary lymph node dissection in T1/T2 breast cancer surgery

Cancer Research

Volumn 73, Issue 24, 2013, Pages 7156-7160

  Sabel, Michael S ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; BREAST CONSERVATION SURGERY; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL EFFECTIVENESS; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; REGIONAL METASTASIS; REVIEW; STUDY DESIGN; SURGICAL MORTALITY;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84891274129     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2094     Document Type: Review

References (24)

1. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy and total mastectomy followed by irradiation. N Eng J Med 2002;347:567-75.
2. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node negative patientswith breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 2010;11:927-33.
3. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. J Natl Cancer Inst 2006;98:599-609.
4. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: An overview of the randomized trials. Lancet 2005;366:2087-106.
5. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: Implications of the ACOSOGZ0011 trial. Semin Surg Oncol 2001;20:230-7.
6. Latosinsky S, Berrang TS, Cutter CS, George R, Olivotto I, Julian TB, et al. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. Can J Surg 2012;55:66-9.
7. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel- node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. Lancet Oncol 2013;14:297-305.
8. Rutgers EJ, Donker M, Straver ME, Meijnen P, Van De Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: Final analysis of the EORTC AMAROS trial (Abstract). J Clin Oncol 2013;31:LBA1001.
9. Whelan TJ, Olivotto I, Ackerman I, Chapman W, Chua B, Nabid A, et al. NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer (Abstract). J Clin Oncol 2011;29:LBA1003.
10. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353: 1641-8.
11. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949-55.
12. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20 year results of the British Columbia randomized trial. JNCI 2005;97:116-26.
13. Aristei C, Chionne F, Marsella AR, Alessandro M, Rulli A, Lemmi A, et al. Evaluation of level I and II axillary nodes included in the standard breast tangential fields and calculation of the administerd dose: Results of a prospective study. Int J Radiat Oncol Biol Phys 2001;51:69-73.
14. Schlembach PJ, Buchholz TA, Ross MI, Kirsner SM, Salas GJ, Strom EA, et al. Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys 2001;51:671-8.
15. Hasselle MD, Dorn PL. Letter to the Editor - axillary vs. sentinel lymph node dissection for invasive breast cancer. JAMA 2011;305:2289.
16. Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig B, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 2003;10: 248-54.
17. Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, et al. Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 2012;255:109-15.
18. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occult metastases on survival in node-negative breast cancer. N Eng J Med 2011;364:412-21.
19. Cody HS, Houssami N. Axillary management in breast cancer: what's new for 2012 Breast 2012;21:411-5.
20. Cools-Lartigue J, Meterissian S. Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: A review. World J Surg 2012;36:46-54.
21. Straver ME, Meijnen P, Van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010;28:731-7.
22. Aigner J, Smetanay K, Hof H, Sinn HP, Sohn C, Schneeweiss A, et al. Omission of axillary dissection according to ACOSOG Z0011: Impact on adjuvant treatment recommendations. Ann Surg Oncol 2013;20: 1538-44.
23. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive post-menopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 2010;28:1829-34.
24. Albain KS, Barlow W, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogenreceptor positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.